A pipeline of therapies for cystic fibrosis.
Seminars in respiratory and critical care
medicine
, 2009 Oct: 611-26
Early anti-pseudomonal acquisition in young patients with
cystic fibrosis: rationale and design of the EPIC clinical trial
and observational study'.
Contemporary clinical trials
, 2009 May: 256-68
Impact of Pseudomonas and Staphylococcus infection on
inflammation and clinical status in young children with cystic
fibrosis.
The Journal of pediatrics
, 2009 Feb: 183-8
Pseudomonas aeruginosa lasR mutants are associated with
cystic fibrosis lung disease progression.
Journal of cystic fibrosis : official journal of
the European Cystic Fibrosis Society
, 2009 Jan: 66-70
Phase 2 randomized safety and efficacy trial of nebulized
denufosol tetrasodium in cystic fibrosis.
American journal of respiratory and critical
care medicine
, 2007 Aug 15: 362-9
Use of lung imaging studies as outcome measures for
development of new therapies in cystic fibrosis.
Proceedings of the American Thoracic
Society
, 2007 Aug 1: 359-63
Outcome measures for development of new therapies in
cystic fibrosis: are we making progress and what are the next
steps?
Proceedings of the American Thoracic
Society
, 2007 Aug 1: 367-9
Advancing outcome measures for the new era of drug
development in cystic fibrosis.
Proceedings of the American Thoracic
Society
, 2007 Aug 1: 370-7
Duration of treatment effect after tobramycin solution for
inhalation in young children with cystic fibrosis.
Pediatric pulmonology
, 2007 Jul: 610-23
Association between pulmonary function and sputum
biomarkers in cystic fibrosis.
American journal of respiratory and critical
care medicine
, 2007 Apr 15: 822-8
Laboratory parameter profiles among patients with cystic
fibrosis.
Journal of cystic fibrosis : official journal of
the European Cystic Fibrosis Society
, 2007 Apr: 117-23
Growth phenotypes of Pseudomonas aeruginosa lasR mutants
adapted to the airways of cystic fibrosis patients.
Molecular microbiology
, 2007 Apr: 512-33
Selection for Staphylococcus aureus small-colony variants
due to growth in the presence of Pseudomonas aeruginosa.
Proceedings of the National Academy of Sciences
of the United States of America
, 2006 Dec 26: 19890-5
Respiratory adverse event profiles in cystic fibrosis
placebo subjects in short- and long-term inhaled therapy
trials.
Contemporary clinical trials
, 2006 Dec: 561-70
Appropriate compensation of pediatric research
participants: thoughts from an Institute of Medicine committee
report.
The Journal of pediatrics
, 2006 Jul: S15-9
Genetic adaptation by Pseudomonas aeruginosa to the
airways of cystic fibrosis patients.
Proceedings of the National Academy of Sciences
of the United States of America
, 2006 May 30: 8487-92
Clinical trial participants compared with nonparticipants
in cystic fibrosis.
American journal of respiratory and critical
care medicine
, 2006 Jan 1: 98-104
Genome mosaicism is conserved but not unique in
Pseudomonas aeruginosa isolates from the airways of young
children with cystic fibrosis.
Environmental microbiology
, 2003 Dec: 1341-9
Pseudomonas acquisition in young patients with cystic
fibrosis: pathophysiology, diagnosis, and management.
Current opinion in pulmonary
medicine
, 2003 Nov: 492-7
Pathophysiology and management of pulmonary infections in
cystic fibrosis.
American journal of respiratory and critical
care medicine
, 2003 Oct 15: 918-51
To cohort or not to cohort: how transmissible is
Pseudomonas aeruginosa?
American journal of respiratory and critical
care medicine
, 2002 Oct 1: 906-7
Pharmacokinetics and bioavailability of aerosolized
tobramycin in cystic fibrosis.
Chest
, 2002 Jul: 219-26